Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
+4.2%<br />
sales growth like-for-like in <strong>2008</strong><br />
14<br />
ACTIVE<br />
Cosmetics<br />
€1,289 million<br />
in sales generated by the division<br />
in <strong>2008</strong><br />
Anticipating<br />
health expectations<br />
in beauty<br />
The goals of the Active Cosmetics<br />
Division are to be the preferred<br />
partner of pharmacists and<br />
dermatologists, roll out its major<br />
brands worldwide and innovate<br />
in its core skincare business.<br />
In a slowing dermocosmetics market, the division<br />
recorded +4.2% like-for-like growth. Western<br />
Europe was down slightly, North America<br />
continued to grow, with a +4.7% rise, and the Rest<br />
of the World zone confirmed its dynamism with<br />
double-digit growth of +14%.<br />
Health, ethics, advice, proximity and value for<br />
money are the watchwords of the division, which<br />
is the market leader. It should benefit from several<br />
favourable factors in 2009, including a unique<br />
portfolio of complementary brands, the richness<br />
of its product innovation, the focusing of resources<br />
and investments on major initiatives and<br />
continuing efforts to boost productivity in<br />
organisation and purchasing.<br />
VICHY<br />
After a slow start to the year, VICHY enjoyed a<br />
more dynamic second half thanks to major<br />
innovations in facial skincare: LiftActiv CxP, an<br />
anti-wrinkle firming care product; Normaderm,<br />
an anti-imperfections moisturiser with an<br />
improved formula; Aqualia, boosted by the arrival<br />
of Aqualia Thermal Mineral Balm. In haircare,<br />
the launch of Aminexil Energy to treat premature<br />
hair loss confirmed VICHY as the leader in this<br />
segment. Number 1 in pharmacy sales in Europe,<br />
Asia and Latin America, VICHY continued its<br />
roll-out in the United States in <strong>2008</strong>.<br />
—VICHY<br />
LiftActiv CxP.